Revel Pharmaceuticals, a San Francisco, CA-based longevity therapeutics company developing enzymes to repair damage from aging, raised $8.4M in Seed financing.
The round was led by Kizoo Technology Capital, and Starbloom Capital with participation from Tubus LLC.
The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.
Today, enzymes are applied therapeutically in only a handful of applications, including for lysosomal storage disorders (Cerezyme), cancer (Asparaginase), and cystic fibrosis (DNase). Revel Pharmaceuticals is reimagining how enzymes can be used as therapeutics by developing repair-based approaches to aging and disease.
Led by Dr. Aaron Cravens, cofounder and CEO, Revel Pharmaceuticals is a biotechnology company with a technology platform based on the work of Yale Professors David Spiegel and Jason Crawford. It is commercializing therapeutic designer enzymes to degrade molecular damage that accumulates in multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes.
FinSMEs
17/03/2022